Science’s 2023 Breakthrough of the Year: Weight loss drugs with a real shot at fighting obesity

Science | AAAS·Dec 14

This story is reported by Science | AAAS. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases

Nature·Jan 7

2

Science’s 2023 Breakthrough: GLP-1 Agonists Show Promise Against Obesity-Associated Disease

American Association for the Advancement of Science (AAAS)·Dec 15

3

Two genetic variants linked to the effects of GLP-1 drugs for obesity

Science Media Centre España·Apr 8

4

Most quit breakthrough weight-loss drug within a year

ScienceDaily·Sep 14

5

How a ‘blockbuster’ treatment for diabetes and obesity might slow or stop Parkinson’s

Van Andel Institute·Feb 15

6

‘Science’ names anti-obesity drugs the scientific breakthrough of the year

EL PAÍS English·Dec 14

7

‘A true breakthrough’: The eye-opening potential of GLP-1 agonists to treat heart, kidney disease in addition to obesity

Cardiovascular Business·Dec 15

8

Q&A: Can weight loss drugs help in addiction treatment?

Penn State Health News·Apr 11